source
- Lilly-backed TRex Bio raises $117M in IPO as hypertension biotech Retension secures $45M listingTRex Bio, a biotech backed by Eli Lilly, completed its initial public offering, generating $116.7 million in gross proceeds. The company sold 8.3 million shares at $14 each, landing at the lower en…
- Aspen Neuroscience and Bambusa Therapeutics announce plans to go public amid biotech IPO surgeAspen Neuroscience, a cell therapy company backed by Gilead, and Bambusa Therapeutics, an I&I biotech founded by former BioNTech scientists, have each filed paperwork to launch initial public offer…